Related references
Note: Only part of the references are listed.Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden A Nonrandomized Controlled Trial
Mariano Provencio et al.
JAMA ONCOLOGY (2023)
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
Joao V. Alessi et al.
JOURNAL OF THORACIC ONCOLOGY (2023)
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
L. E. Hendriks et al.
ANNALS OF ONCOLOGY (2023)
Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC
T. S. K. Mok et al.
ANNALS OF ONCOLOGY (2023)
Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma
D. Boiarsky et al.
ANNALS OF ONCOLOGY (2023)
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
Namrata S. Patil et al.
CANCER CELL (2022)
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Biagio Ricciuti et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Targeting STING for cancer immunotherapy: From mechanisms to translation
Ruilei Huang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2022)
Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes
Aleksandr Zaitsev et al.
CANCER CELL (2022)
Leveraging big data of immune checkpoint blockade response identifies novel potential targets
Y. Bareche et al.
ANNALS OF ONCOLOGY (2022)
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
Shunsuke Kitajima et al.
CANCER CELL (2022)
Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer
Pietro Rosellini et al.
EUROPEAN JOURNAL OF CANCER (2022)
OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC
S. Peters et al.
Journal of Thoracic Oncology (2022)
RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma
Philip East et al.
NATURE COMMUNICATIONS (2022)
Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status
S. S. Ramalingam et al.
ANNALS OF ONCOLOGY (2021)
Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy
Caicun Zhou et al.
CLINICAL CANCER RESEARCH (2021)
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
Alessandro Di Federico et al.
EUROPEAN JOURNAL OF CANCER (2021)
Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation
Wei Nie et al.
ONCOIMMUNOLOGY (2021)
Pan-cancer single cell landscape of tumor-infiltrating T cells
Liangtao Zheng et al.
SCIENCE (2021)
Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker
Elena Fountzilas et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Nabendu Pore et al.
CANCER DISCOVERY (2021)
Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient
I. Domingues et al.
PULMONOLOGY (2020)
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
Carminia M. Della Corte et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Molecular mechanisms and cellular functions of cGAS-STING signalling
Karl-Peter Hopfner et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Michael A. Gillette et al.
CELL (2020)
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
D. Marinelli et al.
ANNALS OF ONCOLOGY (2020)
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
Yunpeng Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Two Patients With Advanced-Stage Lung Adenocarcinoma With Radiologic Complete Response to Nivolumab Treatment Harboring an STK11/LKB1 Mutation
Ernest Nadal et al.
JCO PRECISION ONCOLOGY (2020)
Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment
Cristina Borzi et al.
PHARMACEUTICALS (2020)
STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort
Simon Papillon-Cavanagh et al.
ESMO OPEN (2020)
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
Arnaud Jeanson et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
Brian C. Miller et al.
NATURE IMMUNOLOGY (2019)
Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer
Wenfeng Fang et al.
CLINICAL CANCER RESEARCH (2019)
Benchmark and integration of resources for the estimation of human transcription factor activities
Luz Garcia-Alonso et al.
GENOME RESEARCH (2019)
LKB1 Mutations in Metastatic Non-Small Cell Lung Cancer (mNSCLC): Prognostic Value in the Real World
A. Golozar et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
Shunsuke Kitapma et al.
CANCER DISCOVERY (2019)
TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma
Jerome Biton et al.
CLINICAL CANCER RESEARCH (2018)
Perturbation-response genes reveal signaling footprints in cancer gene expression
Michael Schubert et al.
NATURE COMMUNICATIONS (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang et al.
NATURE MEDICINE (2018)
Concurrent Mutations in STK11 and KEAP1 is Associated with Resistance to PD-(L) 1 Blockade in Patients with NSCLC Despite High TMB
K. Arbour et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies
Marco Mina et al.
CANCER CELL (2017)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2015)
Type I interferons in anticancer immunity
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2015)
LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT
Jacob M. Kaufman et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
S. Dearden et al.
ANNALS OF ONCOLOGY (2013)
GSVA: gene set variation analysis for microarray and RNA-Seq data
Sonja Haenzelmann et al.
BMC BIOINFORMATICS (2013)
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
David B. Shackelford et al.
NATURE REVIEWS CANCER (2009)